China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Long-Term Capital Lease Obligation : ¥32 Mil (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is China Resources Double-Crane Pharmaceutical Co Long-Term Capital Lease Obligation?

China Resources Double-Crane Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥32 Mil.

China Resources Double-Crane Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (¥39 Mil) to Dec. 2023 (¥30 Mil) but then increased from Dec. 2023 (¥30 Mil) to Mar. 2024 (¥32 Mil).

China Resources Double-Crane Pharmaceutical Co's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (¥35 Mil) to Dec. 2022 (¥33 Mil) and declined from Dec. 2022 (¥33 Mil) to Dec. 2023 (¥30 Mil).

China Resources Double-Crane Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for China Resources Double-Crane Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Double-Crane Pharmaceutical Co Long-Term Capital Lease Obligation Chart

China Resources Double-Crane Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

121.94

35.43

32.93

29.95

China Resources Double-Crane Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															56.45	29.44	39.47	29.95	31.67

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

China Resources Double-Crane Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of China Resources Double-Crane Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Double-Crane Pharmaceutical Co Ltd (SHSE:600062) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102

Website

http://www.dcpc.com

China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Headlines

No Headlines